Search
Lobaplatin
go.drugbank.com/drugs/DB13049InvestigationalLobaplatin has been used in trials studying the treatment of Breast Cancer, Hepatocellular Carcinoma, and Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma.
Apitegromab
go.drugbank.com/drugs/DB16096InvestigationalApitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).
Mapatumumab
go.drugbank.com/drugs/DB18945InvestigationalMapatumumab is under investigation in clinical trial NCT00094848 (Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-hodgkin's Lymphoma (NHL)).
MIV-701
go.drugbank.com/drugs/DB05736ExperimentalMIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.
Enarodustat
go.drugbank.com/drugs/DB14985InvestigationalEnarodustat is under investigation in clinical trial NCT02581124 (Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease).
IL-2 pDNA
go.drugbank.com/drugs/DB05935ExperimentalVical incorporated has initiated a human Phase 1 study of an investigational method of delivering interleukin-2 (IL-2), a potent immune system stimulant, for patients with recurrent metastatic melanoma
5-O-phosphono-alpha-D-ribofuranosyl diphosphate
go.drugbank.com/drugs/DB01632ApprovedWithdrawnThe key substance in the biosynthesis of histidine, tryptophan, and purine and pyrimidine nucleotides.
Synonyms: 5-O-phosphono-α-D-ribofuranosyl diphosphate, 5-O-phosphono-alpha-D-ribofuranosyl diphosphateCustirsen
go.drugbank.com/drugs/DB05487InvestigationalCustirsen is also being investigated in the treatment of primary brain tumors. … This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor-related mechanisms.
Repinotan
go.drugbank.com/drugs/DB06506InvestigationalRepinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.
Nangibotide
go.drugbank.com/drugs/DB16247InvestigationalNangibotide is under investigation in clinical trial NCT04055909 (Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock).